don from pa

[don from pa @tbvbxbpyk6]

@DanBrickner2 @OzzieChambers It seems likely that Azer Cell information will be presented, but it may come on October 21 as a late breaking news. Or oct 7 as an abstract. Or it may not be ready yet.

[don from pa @tbvbxbpyk6]

@stuhar5 Next week, the shorts need to start to cover. The following week on October 7 will see the release of EcTRIMS abstracts.

[don from pa @tbvbxbpyk6]

@semodough Embargo on abstracts ends October 7. Hope for good news then.

[don from pa @tbvbxbpyk6]

@no_liquidity @semodough @TGTherapeutics That would be more of a ringside chat.

[don from pa @tbvbxbpyk6]

@DanBrickner2 @EL_Goeffrey

[don from pa @tbvbxbpyk6]

@semodough Come for Briumvi, Stay for Azer-cel!

[New York Post @nypost]

Dodgers trading for Tarik Skubal in yet another blockbuster move in three-peat quest https://t.co/eXROOQqiNo

[don from pa @tbvbxbpyk6]

@Lucy3370 Thanks for your comments

[don from pa @tbvbxbpyk6]

@Lucy3370 No. Better drug. Others cannot replicate or they would have already

[don from pa @tbvbxbpyk6]

@semodough https://t.co/6bPSpAuH9c

[don from pa @tbvbxbpyk6]

@2000STOCKMASTER The phase, one bio availability data, which should come out any day now for subcutaneous formulation should give us a big boost.

[don from pa @tbvbxbpyk6]

@TroyTiger @WallStSai It should work like rituxin. They will unleash its oncologist potential!

[don from pa @tbvbxbpyk6]

@JoelFKorytko God bless you all and prayers for MRD

[don from pa @tbvbxbpyk6]

@2000STOCKMASTER It makes sense that the future value of the sales can be calculated now that preliminary sub q data is in. It is also likely that a rough number can be put on car-t. I think the company is now ready for sale.

[don from pa @tbvbxbpyk6]

@WasatchSnow Can you still ski at Snowbird and will they close early?

[don from pa @tbvbxbpyk6]

$tgtx

[Imugene | Cancer Immunotherapies @TeamImugene]

Next-gen cancer therapies require precision, scale and regulatory alignment.

Our CEO, Leslie Chong, recently discussed our azer-cel platform strategy and development pathways at the ASX Gem Conference.

Watch: https://t.co/NpflbQZn3E

#ImmunoOncology #Biotech #CancerTherapy #Imugene

[DNAternal @dheurofkshe]

$DTIL $IMU MAJOR Azer-cel trial update

NCT03666000 quietly adds CLL/SLL and a CAR-T–naïve Phase 1b expansion cohort alongside the CAR-relapsed group. This shifts the study from pure salvage biology to 2L+ BNHL much bigger markets!! #bullish

https://t.co/mDjTOUADLH

[don from pa @tbvbxbpyk6]

@Chat3Free No

o

[don from pa @tbvbxbpyk6]

@zipjet Great write up. One addition I have is that there’s no value associated with this drug fot other rheumatologic conditions which will probably come to pass.